AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04908111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-MAGEA3
Description: Patients commence their Standard of Care (SoC) chemotherapy in combination with an immune checkpoint inhibitor in 3 weekly cycles. Patients are screened during the first 2 cycles of SoC treatment to confirm eligibility for the trial.~Patients who receive trial vaccines (safety run in stage, Arm A of the NSCLC randomisation cohort and Squamous Oesophageal Cancer Cohort) continue to receive their SoC treatment plus:~* First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of SoC treatment.~* First boost MVA-MAGEA3 vaccine, and if applicable a first boost MVA-NYESO vaccine, 21 days later.~* For patients who have not progressed: second prime ChAdOx1-MAGAEA3-NYESO vaccine 15 weeks following first prime vaccine~* Second boost MVA-MAGAE3 vaccine, and if applicable a second boost MVA-NYESO vaccine, 21 days following second prime vaccine~Patients in Arm B of the NSCLC randomisation cohort will continue to receive their SoC treatment only throughout the trial (i.e. no trial vaccines)
Study NCT04908111 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Standard of care treatment
Description: Patients will continue to receive standard of care treatment (chemotherapy and checkpoint inhibitor).
Study NCT04908111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NYESO
Description: Patients commence their Standard of Care (SoC) chemotherapy in combination with an immune checkpoint inhibitor in 3 weekly cycles. Patients are screened during the first 2 cycles of SoC treatment to confirm eligibility for the trial.~Patients who receive trial vaccines (safety run in stage, Arm A of the NSCLC randomisation cohort and Squamous Oesophageal Cancer Cohort) continue to receive their SoC treatment plus:~* First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of SoC treatment.~* First boost MVA-MAGEA3 vaccine, and if applicable a first boost MVA-NYESO vaccine, 21 days later.~* For patients who have not progressed: second prime ChAdOx1-MAGAEA3-NYESO vaccine 15 weeks following first prime vaccine~* Second boost MVA-MAGAE3 vaccine, and if applicable a second boost MVA-NYESO vaccine, 21 days following second prime vaccine~Patients in Arm B of the NSCLC randomisation cohort will continue to receive their SoC treatment only throughout the trial (i.e. no trial vaccines)
Study NCT05393934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High dense nutrients formula
Description: High dense nutrients formula: Powder based Infant formula with High Nutrients' Density with energy density of 100 kcal/100ml and for Pediatric Nutrition Care: A medical service to understand nutritional status, problems related to the feeding process and clinical diagnosis of the patient.
Study NCT05393934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pediatric Nutrition Care (PNC)
Description: Pediatric Nutrition Care: A medical service to understand nutritional status, problems related to the feeding process and clinical diagnosis of the patient.
Study NCT05393934 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pediatric Nutrition Care (PNC)
Description: Pediatric Nutrition Care: A medical service to understand nutritional status, problems related to the feeding process and clinical diagnosis of the patient.
Study NCT06355843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: PSMA is located in prostate epithelial cells and is converted to a membrane-bound protein in prostate cancer, and PSMA expression is approximately 100 to 1000 times higher in prostate cancer tissue compared to normal prostate tissue. PSMA is expressed at high levels in 95% of prostate cancer patients and is upregulated in castration-resistant prostate cancer (CRPC) and metastatic prostate cancer. PSMA expression was also increased after androgen deprivation therapy (ADT). The use of positronuclide 68Ga-labelled PSMA small molecule inhibitors can be specifically combined with prostate cancer cells, and it is important for the diagnosis of prostate cancer and its metastatic foci through PET/CT and PET/MR visualisation.~With the popularity of integrated PET/MR imaging, combining the higher resolution and morphological performance of MR imaging with the N-staging and M-staging of PET, the specificity of primary prostate cancer diagnosis can be greatly improved.
Study NCT05556642 — intervention group
Intervention type: OTHER
Intervention: Biospecimen collection
Description: Clinical information and biospecimens will be collected
Study NCT04118556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decidua Stroma Cells (DSC)
Description: Placenta-derived Decidua Stroma Cells. The product consists of a viable allogeneic DSCs frozen in 5% of human serum albumin (HSA) in sodium chloride (NaCl) 0.9% and 10% dimethylsulfoxide (DMSO), that is thawed and immediately diluted in 40 mL sodium chloride (NaCl) 0.9% prior to infusion. That will give a final concentration of 2.2% HSA and 2% DMSO.~DSC will be infused when steroid-refractory acute GVHD after allogenic stem-cell transplantation has been diagnosed. Two doses, one week apart, will be given to all patients. Additional doses will be used depending on response.
Study NCT04118556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best available Treatment (BAT)
Description: The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
Study NCT05853211 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Aligner and inter-arch elastics
Description: Correction of class II malocclusion by class II elastics on clear aligners
Study NCT06516185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: direct-printed aligner
Description: Patients will be treated with direct-printed aligners until dental alignment is achieved.
Study NCT06516185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thermoformed aligner
Description: Patients will be treated with thermoformed aligners until dental alignment is achieved.
Study NCT05708183 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Multiple micronutrient supplementation (MMS)
Description: Ethiopia will distribute the UNIMMAP (United Nations International Multiple Micronutrient Antenatal Preparation) formulation that includes 30mg iron. The supplement contains 15 essential vitamins and minerals including: Retinol (Vitamin A-acetate) 800 μg; Vitamin E (as vitamin E-acetate) 10 mg; Vitamin D (as Cholecalciferol) 200 IU; Vitamin B1 (Thiamine mononitrate) 1.4 mg; Vitamin B2 (As Riboflavin) 1.4 mg; Vitamin B3 (As Nicotinamide) 18 mg; Vitamin B6 (as Pyridoxine 1.9 mg; Vitamin B12 (as Cyanocobalamin) 2.6 mg; Folic Acid 400 μg; Vitamin C (As Ascorbic Acid) 70 mg; Iron (As ferrous sulphate) 30 mg; Zinc (As zinc sulphate) 15 mg; Copper (as Copper Sulphate) 2 mg; Selenium (as Sodium selenite) 65 μg; Iodine (as Potassium Iodate) 150 μg.
Study NCT05708183 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Iron folate supplementation (IFA)
Description: IFA delivered as part of routine antenatal care, according to current policy
Study NCT05245045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shengtaibufen Photodynamic Therapy(STBF-PDT)
Description: Shengtaibufen Photodynamic Therapy(STBF-PDT)
Study NCT05245045 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Red light
Description: Red light
Study NCT04317716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fall prevention program
Description: The intervention consists of the fall prevention program for ambulatory and non-ambulatory people with multiple sclerosis. The program will be group-based with 6-8 participants, led by a facilitator, and performed online. It comprises six two-hour sessions held once a week, and a booster session held eight weeks after the sixth session. In addition they will receive a brochure about falls and fall risk factors.
Study NCT04317716 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brochure about falls and fall risk factors
Description: Control-group participants will receive a brochure about fall risk factors and fall prevention in addition to the standard MS care and rehabilitation.
Study NCT04001998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-2660
Description: Randomized to active product
Study NCT05088538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: After completing the necessary forms, it is planned to give the QR-coded education booklet prepared by the researcher to the patients and to inform the patients and their relatives about the use of QR codes. At that time, it is planned that the teaching will be carried out using various training methods such as lecture, question-answer, demonstration and practice. It is thought that the teaching will be divided into 3 parts: pre-operative, post-operative and discharge. According to the physical conditions of the clinic, it is planned to provide patient education in an suitable area for teaching as much as possible. Patients will be reminded that they can access the information whenever they want and as many times as they want by scanning the QR code from their phone.
Study NCT06248112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril and Valsartan-Test product
Description: Test-Product: Sacubitril 97 mg and Valsartan 103 mg film-coated tablets Manufactured by: Hetero Labs Ltd., India
Study NCT06248112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril and Valsartan-Reference product
Description: Reference-product: ENTRESTOTM (Film-Coated Tablets) 97/103 mg Manufactured by: Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd., Singapore for Novartis Pharma AG, Basle, Switzerland
Study NCT04684966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Standart pulmonary rehabilitation with combined quadriceps and triceps surae ESNM using two identical electrotherapy devices allowing simultaneous stimulation of the quadriceps and triceps (EG group).
Study NCT04684966 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Neuromuscular Electrical Stimulation
Description: Standart pulmonary rehabilitation with combined sham NMES of the quadriceps and triceps surae performed using two identical electrotherapy devices allowing simultaneous stimulation of the quadriceps and triceps (CG group)
Study NCT06551168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat exposure
Description: Participants will exercise at home while wearing a clothing ensemble over 19 one hour sessions. They will use validated perceptual scales to guide their effort and thermal sensation.
Study NCT06551168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants will exercise at home over 19 one hour sessions. They will use heart rate to guide their effort. The exercise will take place in cool conditions
Study NCT06002633 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Participants will consume beverages containing alcohol.
Study NCT06002633 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume beverages containing a very low dose of alcohol (placebo condition).
Study NCT06014047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No-touch vein graft
Description: Two No-touch saphenous vein grafts anastomose to the right coronary and left coronary system. All participants also acquired Left intrathoracic artery(LITA)-left anterior decending artery(LAD) anastomosis to complete the revascularization.
Study NCT06014047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial artery graft
Description: One radial artery graft and one conventional saphenous vein graft anastomose to the right coronary or left coronary system basing on surgeons' decision. All participants also acquired Left intrathoracic artery(LITA)-left anterior decending artery(LAD) anastomosis to complete the revascularization.
Study NCT05226234 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: Late gadolinium enhancement cardiac magnetic resonance (LGE-MRI)
Study NCT04910672 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Bilateral global pelvic manipulation. Lower right limb in extension. The left lower limb in flexion, until the tension on the SPIS was felt. Introduce very little rotation of the spine. ASI anterior slide until crease forms at waist.~We bring the elbow towards our hips. We rotate the patient posteriorly to open the lumbo sacral facet. The thrust is performed by simultaneously increasing these three parameters, with kick and joint compression.
Study NCT04910672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Bilateral Global Pelvic Manipulation and Internal Correction Technique for Laterflexion of the Uterus The technique consists of making contact with the vaginal fingers on the upper and anterior part of the cervix, while the abdominal hand, dragging the skin towards the pubis, tries to make contact as posterior as possible on the fundus of the uterus. The technique consists, while the patient breathes widely, in progressively raising the uterine fundus forward and upward and lowering the cervix until the normal anteversion position is achieved.~At the end of the technique, fixing the correction position of the uterus, we can ask the patient to perform a pelvic anteversion, while the correction is maintained. At the end of the technique, all abnormal tension should have disappeared and the uterus should have recovered a physiological position of anteversion.
Study NCT06180902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Inferior vena cava's diameter ratio
Description: In mechanical ventilation, the Inferior Vena Cava's maximum diameter (IVCmax) is measured at peak inspiration, and minimum diameter (IVCmin) at expiration's end. The Distensibility Index (IVCDI) is calculated as \[(IVCmax - IVCmin) / IVCmin\] × 100%. In spontaneous breathing, IVCmax is the diameter at expiration's end, and IVCmin at inspiration's end. The Collapse Index (IVCCI) is \[(IVCmax - IVCmin) / IVCmax\] × 100%.~Clinically, an IVCDI/IVCCI ≥ 18% indicates a 'responder'. Values \< 18% denote 'non-responders'.
Study NCT06180902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Central venous pressure
Description: In our protocol, patients lie flat, connected to a saline-filled system for intravenous infusion via a central venous catheter. The system, starting from the subclavian catheter, extends to the 2nd to 3rd intercostal space at the mid-axillary line. The tube's end is raised perpendicular to the bed until saline flow stops, marking the liquid level. The height from the mid-axillary line to this point is measured in millimeters. If the liquid column falls below the mid-axillary line, indicating continuous flow, the CVP is negative, and the catheter is closed to block air entry. CVP readings are taken at exhalation's end.~CVP interpretation:~* CVP ≤ 12 mmHg (16.3 cm H2O) indicates a responder.~* CVP > 12 mmHg (16.3 cm H2O) indicates a non-responder.
Study NCT06180902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Passive leg raising test
Description: In our protocol, the patient starts flat for initial CVP measurement. Then, the bed is tilted to 45 degrees for the first measurements: Systolic/Diastolic Blood Pressure, Mean Arterial Pressure, and Pulse Pressure (Systolic - Diastolic). Next, the bed is adjusted to elevate the feet, creating a 135-degree angle between torso and legs. After 90 seconds, the second set of measurements, including CVP, is taken. The patient is then returned to the initial position.~Interpreting results:~A responder is indicated by:~* Over 10% Pulse Pressure (PP) increase in the second measurement;~* The ratio of PP change to CVP change (∆PP / ∆CVP) > 1;~* Second measurement CVP ≤ 12 mmHg (16.3 cm H2O).~A non-responder is indicated by the presence at least one of the following:~* Less than 10% PP increase in the second measurement;~* The ratio of PP change to CVP change (∆PP / ∆CVP) ≤ 1;~* Second measurement CVP > 12 mmHg (16.3 cm H2O).
Study NCT06180902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluid challenge
Description: In our clinical procedure, patients start horizontally for initial measurements: Systolic, Diastolic, Mean Arterial, Pulse Blood Pressures, and Central Venous Pressure (CVP). Then, they receive a balanced crystalloid solution at 4 ml/kg body weight at maximum permissible infusion rate. After infusion, a second measurement set identical to the first is taken.~Interpretation:~A responder is indicated by:~* Pulse Pressure (PP) increase > 10% in second measurement;~* Ratio of PP change to CVP change (∆PP / ∆CVP) > 1;~* Second CVP measurement ≤ 12 mmHg (16.3 cm H2O).~A non-responder is indicated by the presence at least one of the following:~* PP increase \< 10% in second measurement;~* Ratio of PP change to CVP change (∆PP / ∆CVP) ≤ 1;~* Second CVP measurement > 12 mmHg (16.3 cm H2O).
Study NCT06180902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid infusion
Description: After assessing infusion therapy responsiveness, patients receive balanced crystalloid solutions at 1000 ml, infused at 15 ml/kg/hour, accounting for any prior infusions. Effectiveness evaluation follows, involving cardiac output reassessment (initially measured upon study enrollment). Effectiveness is determined by a ≥10% increase in cardiac output in the second measurement compared to the first. This is quantified as: \[(CO(after) - CO(before)) / CO(before)\] × 100% ≥ 10%, where CO(after) is the post-infusion cardiac output and CO(before) the pre-infusion output.
Study NCT05388097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Managed Services
Description: coordination of care and assistance with community resources (food, transportation)
Study NCT05848453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAP5191
Description: Placebo
Study NCT05432700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LactApp
Description: LactApp® provides personalised answers that can be arrived at through different pathways, which vary according to the profile of the user and the options she selects, allowing data sampling through an Ecological Momentary Assessment.~The app will remind of:~The first month: baby's breastfeeding position, frequency of feeds, number and consistency of stools, general breast care, average weight gain; in mothers who gave some supplementation, advice and support for them to try re-breastfeeding.~From the second to the third month: advice on expressing milk to create a reserve just in case they went back to work or had to be absent from home for a day, instructions on how to handle and preserve milk.~From the fourth to the sixth month: indications to use the stored milk (if it was created) and techniques for administering it to the infant, the importance of maintaining the EBF and the inadvisability of offering other types of milk or food.
Study NCT05659654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: 250 mg/capsule, 2 capsules per day, for 4 weeks
Study NCT06400004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
Description: Bolus administration of 2 mL undiluted Lumason®, to be administered in 20 seconds
Study NCT06643169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based fall prevention program with multifactorial
Description: * Health Education~* Otago Exercises~* Assessing and Organizing the Safe Home Environment
Study NCT05216926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of preventive action based on prediction model
Description: Timing of preventive action based on prediction model
Study NCT05216926 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hypoglycaemia treatment at hypoglycaemia (usual care)
Description: Hypoglycaemia treatment at hypoglycaemia (usual care)
Study NCT06400004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason
Description: Continuous infusion of 8 mL of diluted Lumason® (4 mL of Lumason® diluted in 4 mL of saline) at a rate of 1.0 mL/min
Study NCT04375813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eRapa
Description: 0.5mg eRapa (encapsulated rapamycin) oral capsules
Study NCT04375813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo capsules visually identical to eRapa oral capsules
Study NCT05390723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communciation intervention
Description: The investigators cannot reveal the manipulated communication as this might influence participant outcomes.
Study NCT05640661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Quest II
Description: active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.~During the realization of the exposure with VRi they will be recorded through an Ipad Tablet, and after performing the entire intervention a terminal visual feedback therapy will be performed by observation of actions in holocentric vision.
Study NCT05640661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oculus Quest II
Description: active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.